TransMedics Group, Inc. (TMDX) saw its stock price soar 5.39% in the post-market trading session on Monday, following the company's robust response to an inaccurate and misleading short-seller report issued by Scorpion Capital.
In a statement, TransMedics vehemently denied the claims made in the report, asserting that it failed to accurately represent the company's business, technology, diverse culture, and steadfast focus on delivering exceptional products and services for organ transplantation. The company defended the integrity of its practices, world-class team, compliance with applicable laws, and unwavering commitment to improving clinical outcomes.
TransMedics highlighted that its OCS technology and NOP program have enabled over 7,000 organ transplants, allowing surgeons to confidently utilize donor organs that would have otherwise been unutilized due to historical technology and logistics limitations. The company's technology and services have driven an expansion in overall U.S. transplant volumes and exceptional post-transplant clinical outcomes, as validated by its extensive clinical data set.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。